Keyphrases
Cost-effectiveness
100%
Pharmacological Therapy
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Cost-effectiveness Analysis
100%
American College of Physicians
100%
Cost-effectiveness Study
100%
Certainty of Evidence
85%
Glucagon-like
71%
Metformin
42%
Risk of Bias
42%
Quality-adjusted Life Years
42%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
42%
First-line Therapy
28%
Assessment Development
28%
Evaluation Assessment
28%
Background Therapy
28%
Grading of Recommendations
28%
Neutral Protamine Hagedorn Insulin
28%
Antidiabetes Medication
28%
United States
14%
Insulin
14%
Evaluation Method
14%
Clinical Practice Guidelines
14%
Dipeptidyl peptidase-4 (DPP-4)
14%
Drug Costs
14%
Assessment Method
14%
Treatment Comparison
14%
Data Extraction
14%
Data Synthesis
14%
Bibliographic Databases
14%
Life-years Gained
14%
Estimated Cost
14%
Funding Sources
14%
Drug Effectiveness
14%
Peptide Agonist
14%
Insulin Analogues
14%
Sulfonylurea
14%
Glucose-dependent Insulinotropic Polypeptide
14%
Drug Comparisons
14%
Uncertain Value
14%
Development Method
14%
Extraction Cost
14%
Metformin Therapy
14%
Approaches Comparison
14%
Antidiabetic Drugs
14%
New Antidiabetic Drugs
14%
Cost Assumptions
14%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Maturity Onset Diabetes of the Young
100%
Systematic Review
100%
Effectiveness Study
100%
Glucagon-Like Peptide-1 Agonist
55%
Health Care Cost
44%
Glycon
44%
Quality Adjusted Life Year
33%
Gastric Inhibitory Polypeptide
33%
Cotransporter
33%
Isophane Insulin
22%
Dipeptidyl Peptidase-4 Inhibitor
11%
Clinical Guideline
11%
Drug Efficacy
11%
Drug Comparison
11%
Anti-Diabetic Medication
11%
Sulfonylurea
11%
Pharmacology, Toxicology and Pharmaceutical Science
Effectiveness Study
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Non Insulin Dependent Diabetes Mellitus
100%
Metformin
80%
Gastric Inhibitory Polypeptide
60%
Cotransporter
60%
NPH Insulin
40%
Sulfonylurea
20%
Drug Comparison
20%
Insulin Analog
20%
Dipeptidyl Peptidase IV Inhibitor
20%
Anti-Diabetic Medication
20%